Active ingredientEtamsylateCat. No. P-E110-001CAS 2624-44-4Family · Pharmaceutical analytical standards
Etamsylate
A haemostatic developed in the early 1960s: it increases the resistance of capillary walls and promotes platelet adhesion. It is used for bleeding from small vessels, such as heavy menstrual bleeding, and to prevent brain haemorrhage in premature babies. This family brings together the active ingredient and other impurities.
Did you know?In 2025 the EMA veterinary committee recommended a medicine based on etamsylate for no fewer than seven species: dogs, cats, horses, cattle, sheep, goats and pigs.
Go to the active ingredient →Active ingredientEtamsylateCat. No. P-E110-001CAS 2624-44-4
ImpurityEtamsylate Impurity 1Cat. No. P-E110-002
ImpurityEtamsylate Impurity 2Cat. No. P-E110-003
ImpurityEtamsylate Impurity 3Cat. No. P-E110-004
ImpurityEtamsylate Impurity 4Cat. No. P-E110-005No product matches your search.
EDQM standards 1
The official European Pharmacopoeia standards for this family.
Reference substanceEtamsylate CRSEDQM code E1830000Family EtamsylateNeed a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.